Moderna fell in trading on Thursday after its vaccine revenues missed analysts’ expectations and the company made a small increase in product sales projections for the year.
While Moderna recorded its first profitable quarter, revenues of $1.94bn came in below Wall Street expectations. The 4.3% increase in projected annual product sales to $19.2bn pales in comparison to the $26bn that rival Pfizer now expects from Covid vaccine sales this year.
The final count depends on the mix of primary two-dose vaccine and booster shots that use less vaccine material.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: